Geron (GERN) Gets Three Patents For Imetelstat In The U.S.
Zacks Investment Research | Jul 14, 2016 12:02AM ET
Geron Corporation (NASDAQ:GERN) announced the issuance of three U.S. patents related to its telomerase inhibitor, imetelstat.
The first patent (U.S. Patent No. 9,375,485) covers imetelstat’s use for alleviating at least one symptom of myelofibrosis or myelodysplastic syndromes, including chronic myelomonocytic leukemia.
The other two patents (U.S. Patent No. 9,388,415 and U.S. Patent No. 9,388,416) are related to the methods of using imetelstat to inhibit the activity of telomerase as well as to inhibit cancer cell proliferation. They also include methods for using imetelstat to treat cancer.
The first patent is expected to be valid till at least Mar 2033, while the other two will run through at least Sept 2024.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.